We found more RSV group B infections among elderly adults than group A. Clinical studies from one candidate vaccine among the elderly, PFP-2 (purified fusion protein), found lower neutralizing titers to group B viruses compared to group A [28]. The gene discussed is PRF1; the disease is infection.